1-3 of 3
Matthew J. Stubbs
Close
Sort by
Journal Articles

Long-term risk of relapse in immune-mediated thrombotic thrombocytopenic purpura and the role of anti-CD20 therapy

CME Clinical Trials & Observations
Andrew J. Doyle, Matthew J. Stubbs, Tina Dutt, Will Lester, Will Thomas, Joost van Veen, Joannes Hermans, Tanya Cranfield, Quentin A. Hill, Amanda Clark, Catherine Bagot, Steven Austin, John-Paul Westwood, Mari Thomas, Marie Scully
Journal: Blood
Blood (2023) 141 (3): 285–294.
https://doi.org/10.1182/blood.2022017023
Published: 2023
Journal Articles

Lactate Utilization Provides a Metabolic Escape to Resist the Antileukemic Activity of BET Inhibition in Acute Myeloid Leukemia

Andrew J. Monteith, Haley E. Ramsey, Dalton Greenwood, Maria P. Arrate, Londa Fuller, Agnieszka E. Gorska, Alexander J. Silver, Donovan J. Brown, Sarah D. Olmstead, Jackson Watke, Matthew J. Stubbs, Jeffrey C. Rathmell, Michael R. Savona
Journal: Blood
Blood (2022) 140 (Supplement 1): 8709–8710.
https://doi.org/10.1182/blood-2022-164701
Published: 2022
Journal Articles

Single Centre UK Comparison of Biosimilar Rituximab (Truxima) with the Originator (MabThera) in Patients with Immune Mediated Thrombotic Thrombocytopenic Purpura

Matthew J. Stubbs, MBBS, MRCP, FRCPath, Ryan Low, MBChB, Siobhan McGuckin, Rosalind Newton, John-Paul Westwood, MD, Mari Thomas, PhD, Simon Cheesman, BPharm, Marie Scully, MD MRCP, FRCPath
Journal: Blood
Blood (2018) 132 (Supplement 1): 3750.
https://doi.org/10.1182/blood-2018-99-114765
Published: 2018